Literature DB >> 16214844

Complement activation-related cardiac anaphylaxis in pigs: role of C5a anaphylatoxin and adenosine in liposome-induced abnormalities in ECG and heart function.

János Szebeni1, Lajos Baranyi, Sándor Sávay, Michael Bodó, János Milosevits, Carl R Alving, Rolf Bünger.   

Abstract

Cardiac anaphylaxis is a severe, life-threatening manifestation of acute hypersensitivity reactions to allergens and drugs. Earlier studies highlighted an amplifying effect of locally applied C5a on the process; however, the role of systemic complement (C) activation with C5a liberation in blood has not been explored to date. In the present study, we used the porcine liposome-induced cardiopulmonary distress model for 1) characterizing and quantifying peripheral C activation-related cardiac dysfunction; 2) exploring the role of C5a in cardiac abnormalities and therapeutic potential of C blockage by soluble C receptor type 1 (sCR1) and an anti-C5a antibody (GS1); and 3) elucidating the role of adenosine and adenosine receptors in paradoxical bradycardia, one of the symptoms observed in this model. Pigs were injected intravenously with different liposomes [Doxil and multilamellar vesicles (MLV)], zymosan, recombinant human (rhu) C5a, and adenosine, and the ensuing hemodynamic and cardiac changes (hypotension, tachy- or bradycardia, arrhythmias, ST-T changes, ventricular fibrillation, and arrest) were quantified by ranking on an arbitrary scale [cardiac abnormality score (CAS)]. There was significant correlation between CAS and C5a production by liposomes in vitro, and the liposome-induced cardiac abnormalities were partially or fully reproduced with zymosan, rhuC5a, adenosine, and the selective adenosine A1 receptor agonist cyclopentyl-adenosine. The use of C nonactivator liposomes or pretreatment of pigs with sCR1 or GS1 attenuated the abnormalities. The selective A1 blocker cyclopentyl-xanthine inhibited bradycardia without influencing hypotension, whereas the A(2) blocker 4-(2-[7-amino-2-(2-furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-5-ylamino]ethyl)phenol (ZM-24135) had no such effect. These data suggest that 1) systemic C activation can underlie cardiac anaphylaxis, 2) C5a plays a causal role in the reaction, 3) adenosine action via A1 receptors may explain paradoxical bradycardia, and 4) inhibition of C5a formation or action or of A1-receptor function may alleviate the acute cardiotoxicity of liposomal drugs and other intravenous agents that activate C.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16214844     DOI: 10.1152/ajpheart.00622.2005

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  21 in total

1.  Bypassing adverse injection reactions to nanoparticles through shape modification and attachment to erythrocytes.

Authors:  Peter Popp Wibroe; Aaron C Anselmo; Per H Nilsson; Apoorva Sarode; Vivek Gupta; Rudolf Urbanics; Janos Szebeni; Alan Christy Hunter; Samir Mitragotri; Tom Eirik Mollnes; Seyed Moein Moghimi
Journal:  Nat Nanotechnol       Date:  2017-04-10       Impact factor: 39.213

Review 2.  In vivo Cell Tracking Using Non-invasive Imaging of Iron Oxide-Based Particles with Particular Relevance for Stem Cell-Based Treatments of Neurological and Cardiac Disease.

Authors:  Markus Aswendt; Jean-Luc Boulland; Jasna Lojk; Stefan Stamenković; Joel C Glover; Pavle Andjus; Fabrizio Fiori; Mathias Hoehn; Dinko Mitrecic; Mojca Pavlin; Stefano Cavalli; Caterina Frati; Federico Quaini
Journal:  Mol Imaging Biol       Date:  2020-12       Impact factor: 3.488

3.  Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management.

Authors:  David Rampton; Joergen Folkersen; Steven Fishbane; Michael Hedenus; Stefanie Howaldt; Francesco Locatelli; Shalini Patni; Janos Szebeni; Guenter Weiss
Journal:  Haematologica       Date:  2014-11       Impact factor: 9.941

Review 4.  To PEGylate or not to PEGylate: Immunological properties of nanomedicine's most popular component, polyethylene glycol and its alternatives.

Authors:  Da Shi; Damian Beasock; Adam Fessler; Janos Szebeni; Julia Y Ljubimova; Kirill A Afonin; Marina A Dobrovolskaia
Journal:  Adv Drug Deliv Rev       Date:  2021-12-10       Impact factor: 15.470

5.  Complement activation by PEGylated single-walled carbon nanotubes is independent of C1q and alternative pathway turnover.

Authors:  Islam Hamad; A Christy Hunter; Kenneth J Rutt; Zhuang Liu; Hongjie Dai; S Moein Moghimi
Journal:  Mol Immunol       Date:  2008-07-03       Impact factor: 4.407

Review 6.  Hypersensitivity to intravenous iron: classification, terminology, mechanisms and management.

Authors:  J Szebeni; S Fishbane; M Hedenus; S Howaldt; F Locatelli; S Patni; D Rampton; G Weiss; J Folkersen
Journal:  Br J Pharmacol       Date:  2015-10-25       Impact factor: 8.739

7.  Suspected Anaphylactic Reaction to Ketamine in 3 Yucatan Swine (Sus scrofa).

Authors:  Chelsea K Wallace; Sara E Bell; Philip C LaTourette; Emily M Miedel; Anthony J Carty; Blythe H Philips
Journal:  Comp Med       Date:  2019-10-04       Impact factor: 0.982

Review 8.  Safety of Nanoparticles in Medicine.

Authors:  Joy Wolfram; Motao Zhu; Yong Yang; Jianliang Shen; Emanuela Gentile; Donatella Paolino; Massimo Fresta; Guangjun Nie; Chunying Chen; Haifa Shen; Mauro Ferrari; Yuliang Zhao
Journal:  Curr Drug Targets       Date:  2015       Impact factor: 3.465

9.  A unique squalenoylated and nonpegylated doxorubicin nanomedicine with systemic long-circulating properties and anticancer activity.

Authors:  Andrei Maksimenko; Franco Dosio; Julie Mougin; Annalisa Ferrero; Severine Wack; L Harivardhan Reddy; Andrée-Anne Weyn; Elise Lepeltier; Claudie Bourgaux; Barbara Stella; Luigi Cattel; Patrick Couvreur
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-02       Impact factor: 11.205

10.  Stealth properties to improve therapeutic efficacy of drug nanocarriers.

Authors:  Stefano Salmaso; Paolo Caliceti
Journal:  J Drug Deliv       Date:  2013-03-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.